Ranibizumab is used in the treatment of wet form of age-related macular degeneration, diabetic macular edema and macular oedema due to retinal vein occlusion.
How it works
Ranibizumab is a monoclonal antibody. It blocks the formation of abnormal blood vessels.
Common side effects
Increased intraocular pressure, Eye pain, Conjunctival hemorrhage, Eye inflammation, Eye floaters
- ₹75000Novartis India Ltd1 variant(s)
- Patients should not drive or use machines immediately after receiving ranibizumab intravitreal injection which may influence the driving ability or ability to operate machines.
- Consult your ophthalmologist immediately if the eye becomes red, sensitive to light, painful or develops a change in vision.
- Before taking ranibizumab, inform you doctor if you are pregnant, planning a pregnancy or breast-feeding.
Frequently asked questions
Q. Is ranibizumab FDA approved?
Yes, ranibizumab is approved by the FDA
Q. What is ranibizumab injection and how does it work?
Ranibizumab injection belongs to a class of medications called vascular endothelial growth factor (VEGF) antagonists. Ranibizumab is used for the treatment of conditions that affect vision such as exudative (wet) neovascular age-related macular degeneration (AMD), macular edema (swelling) following retinal vein occlusion and macular edema (swelling) due to diabetes. Ranibizumab binds extracellular VEGF thereby stopping abnormal blood vessel growth and leakage in the eye(s) which may lead to vision loss in people with wet AMD.